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Abstract
Objective—Disruption of endothelial barrier integrity is a characteristic of many inflammatory 
conditions. However, the origin and function of endothelial cells (ECs) restoring endothelial 
barrier function remain unknown. This study defined the roles of resident ECs (RECs) and bone 
marrow-derived endothelial progenitor cells (BMDEPCs) in endothelial barrier restoration 
following endotoxemic lung injury.
Approach and Results—We generated mice that enable to quantify proliferating RECs or 
BMDEPCs, and also to study the causal link between REC or BMDEPC proliferation and 
endothelial barrier restoration. Using these mouse models, we showed that endothelial barrier 
restoration was associated with increased REC and BMDEPC proliferation. RECs and BMDEPCs 
participate in barrier repair. Immunofluorescence staining demonstrated that RECs proliferate in 
situ on endothelial layer, and that BMDEPCs are engrafted into endothelial layer of lung 
microvessels at active barrier repair phase. In lungs 8 weeks after LPS-induced injury, number of 
REC-derived ECs (CD45−/CD31+/BrdU+/rtTA+) or BMDEPC-derived ECs (CD45−/CD31+/
eNOS+/GFP+) increased by 22- or 121-fold. Suppression of REC or BMDEPC proliferation by 
blocking REC or BMDEPC intrinsic NF-κB at barrier repair phase was associated with an 
augmented endothelial permeability and impeded endothelial barrier recovery. RECs and 
BMDEPCs contributed differently to endothelial barrier repair. In lungs 8 weeks after LPS-
induced injury, REC-derived ECs constituted 22%, but BMDEPC-derived ECs constituted only 
3.7% of the total new ECs.
Conclusions—REC is a major and BMDEPC is a complementary source of new ECs in 
endothelial barrier restoration. RECs and BMDEPCs play important roles in endothelial barrier 
restoration following inflammatory lung injury.
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Introduction
Disruption of endothelial barrier and increase in endothelial permeability are major features 
of acute lung injury (ALI) associated with sepsis, trauma and hemorrhage.1-3 However, the 
mechanisms regulating endothelial barrier restoration are poorly understood. Prior studies 
showed that fox head box M1-regulated proliferation genes play important roles.4, 5 
However, the “effector” cells that mediated the repair function of fox head box M1 have not 
been identified. The origin and function of endothelial cells (ECs) in endothelial barrier 
restoration following inflammatory organ injury remain unknown.
Resident endothelial cell (REC) is long believed to be a major source of ECs in endothelial 
repair. Indeed, neighboring RECs were observed to sprout into denuded area after 
mechanical arterial endothelial denudation.6 However, the role of RECs in the restoration of 
endothelial barrier function after organ injury has not been studied. A causal link between 
REC proliferation and endothelial barrier restoration remains to be established. Bone 
morrow derived endothelial progenitor cells (BMDEPCs) as a source of ECs in angiogenesis 
and endothelial repair has been extensively studied, although whether BMDEPCs contribute 
to endothelial or vascular wall is controversial.7-16 Depending on type, nature and severity 
of the injury, BMDEPCs were reported to contribute to endothelial and vascular repair in 
some experimental models,7-13 but play no role in other models.13-16 Microvascular injury 
associated with septic ALI differs significantly from models used in prior reports in nature 
and severity. The contribution of BMDEPCs to endothelial barrier repair in septic organ 
injury is still unclear. Increased EPC mobilization and/or recruitment were observed in 
patients17, 18 and animal models8 with septic organ injury. Autologous transplantation of 
EPCs suppressed lung inflammation, attenuated endothelial permeability and lung edema, 
and improve outcomes.19, 20 However, it remains unclear whether the exogenous EPCs 
improve endothelial barrier function by preventing endothelial injury or by promoting 
endothelial repair, or by both. Other investigators have demonstrated that exogenously 
administered EPCs or other stem/progenitor cells did not participate in endothelial repair, 
but alleviated organ injury and improved outcomes by immunomodulating and paracrine 
mechanisms. 21-24 Furthermore, no prior study has examined the causal link between 
BMDEPC recruitment/proliferation and endothelial barrier restoration. Thus, whether 
BMDEPC is a source of ECs in endothelial barrier restoration remains unclear.
To study the causal link between REC or BMDEPC proliferation and endothelial barrier 
restoration, we need to examine the functional effect of inhibiting REC or BMDEPC 
proliferation on endothelial barrier restoration. Additionally, barrier injury and repair are 
interrelated. Severity of injury determines the extent of repair. It is ideal to inhibit REC or 
BMDEPC proliferation only at barrier repair phase. Animal model that enables to selectively 
inhibit REC or BMDEPC proliferation at barrier repair phase are needed. No such an animal 
model has been reported.
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In this study, we took advantage of the fact that endothelial repair depends mainly on 
proliferation of EC precursor cells and that the NF-κB pathway is a major pathway 
controlling cell proliferation.25-30 We created EC-I-κBα-WT-BM or WT-EC-I-κBα-BM 
chimeric mice with doxycycline (Dox)-inducible and REC- or BMDEPC-restricted 
overexpression of a mutant I-κBα (I-κBαmt). By treating these mice with Dox after peak of 
lung injury, we were able to inhibit REC or BMDEPC proliferation at barrier repair phase 
by blocking REC or BMDEPC intrinsic NF-κB activity in a cell-targeted and stage-specific 
manner. By performing cause-to-effect studies in combination with cell fate mapping, we 
demonstrated that REC is a major and BMDEPC is a complementary source of new ECs in 
endothelial barrier repair, and that RECs and BMDEPCs play important roles in endothelial 
barrier restoration following inflammatory ALI.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Active endothelial barrier repair occurs at 48 hours
Endothelial permeability increased progressively between 0 and 24 hours, associated with 
increasing numbers of apoptotic ECs, and decreased progressively between 24 and 96 hours, 
associated with decreasing numbers of apoptotic ECs and increasing numbers of 
proliferating ECs (Figure 1A, Ref. 30). Based on those observations, we defined 0-24 and 
24-96 hours, respectively, as endothelial barrier injury and repair phases. At 48 hours, 
endothelial permeability decreased rapidly, associated with the highest level of EC 
proliferation (Figure 1A, Ref 30). We considered 48 hour as active barrier repair phase, and 
focused our subsequent studies on 48 hours.
Endothelial barrier recovery is associated with increased REC and BMDEPC proliferation
If RECs and BMDEPCs play important roles in endothelial barrier repair, number of 
proliferating RECs or BMDEPCs should increase at active repair phase. To track 
proliferating RECs or BMDEPCs in vivo, we generated EC-rtTA-GFP-BM chimeras by 
transplanting lethally irradiated EC-rtTA mice31 with bone marrows (BMs) from Tie2-GFP 
mice (Supplemental Table I and Table II). These chimeras overexpress the reverse 
tetracycline transactivator (rtTA) on RECs and green fluorescent protein (GFP) on 
BMDEPCs. Fluorescence activated cell sorting (FACS) analysis of BM mononuclear cells 
(BMMNCs) from donors and chimeras 2 months later confirmed that 95% of BM cells in 
the chimeras were donor BM origin (Supplemental Figure IA). FACS analysis of peripheral 
blood mononuclear cells further confirmed the high degree of BM chimerism in the EC-
rtTA-GFP-BM mice (data not shown).
The endothelial-specific Tie2 promoter drives GFP expression in endothelial lineage cells. 
However, Tie2 was reported to be expressed on a subset of monocytes/macrophages.32 To 
clarify the percentage of monocytes in the GFP+ cell population in the lungs, we phenotyped 
GFP+ cells from lungs of Tie2-GFP donor mice 48 hours after LPS challenge. We found 
that 99% of the GFP+ cells are CD45−/CD31+/eNOS+ endothelial lineage cells, and less 
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than 1% of them are CD45+/CD31+ hematopoietic cells (Supplemental Figure II). Our 
finding is consistent with a prior report.15 Thus, GFP+ cells in the EC-rtTA-GFP-BM mice 
represent principally BMDEPCs.
Two months after BM transplantation, mice were injected with saline or LPS, and then with 
bromodeoxyuridine (BrdU) to label proliferating cells in vivo. Proliferating RECs or 
BMDEPCs, or recruited BMDEPCs were identified by BrdU/rtTA or BrdU/GFP double 
staining, or by GFP staining, and counted. Time course analyses showed that endothelial 
barrier recovery was associated with remarkably increased REC and BMDEPC proliferation 
(Figure 1). In particular, the high numbers of proliferating RECs and BMDEPCs at 48 hours 
were concordant with 48 hours being active barrier repair phase. No significant numbers of 
proliferating RECs and BMDEPCs were detected at 12 (injury phase) or 96 hours (barrier 
function recovered) (Figure 1). ALI was associated with an increased recruitment of GFP+ 
BMDEPCs in lungs (Figure 1D). However, BMDEPC recruitment was not correlated with 
barrier recovery, but correlated with barrier injury (Figures. 1A vs 1D), suggesting that ALI 
stimulates BMDEPC recruitment.
RECs participate in endothelial barrier repair
If RECs participate in endothelial barrier repair, these cells should proliferate in situ on 
endothelial layer at active repair phase to give rise to new ECs. Furthermore, the REC-
derived daughter ECs should significantly increase in lungs after recovery from injury. EC-
rtTA-GFP-BM mice that overexpress rtTA only on RECs (Supplemental Table II) were 
injected with BrdU at 44 hours after LPS injection to label proliferating cells. Lungs were 
harvested at 48 hours or at 8 weeks after LPS injection to track the location of proliferating 
RECs or to quantify the REC-derived new ECs in lungs. We visualized endothelial layer by 
immunofluorescence staining (IF) of lung sections with rtTA or CD31 antibody. We 
identified proliferating RECs by BrdU and rtTA double IF staining. Confocal microscopic 
examination revealed that BrdU+/rtTA+ proliferating RECs were localized on the 
endothelial layer of microvessels (Figure 2A). The BrdU+/rtTA+ proliferating RECs co-
expressed EC marker, CD31, and were localized on the CD31+ endothelial layer, but were 
not localized on the aquaporin-5 (Aqu5)+ epithelial layer (Figure 2A). This result provides 
histological evidence that RECs proliferate in situ on endothelial layer at active barrier 
repair phase
FACS analysis showed that number of REC-derived new ECs (CD45−/CD31+/BrdU+/rtTA
+) was approximately 22-fold higher in lungs of EC-rtTA-GFP-BM mice 8 weeks after LPS-
induced injury, compared to lungs from mice 8 weeks after saline injection (Figures 2B and 
2C). These results provide cytological evidence for REC's participation in endothelial barrier 
repair.
BMDEPCs contribute to endothelial barrier repair
BMDEPC incorporation into endothelial layer is a critical step in BMDEPC-mediated 
endothelial repair. To seek histological evidence of BMDEPC engraftment, we stained lung 
sections from mice 48 hours after LPS injection with antibodies against BMDEPC marker, 
GFP, EC markers, CD31 and Ve-cadherin (Ve), or alveolar epithelial cell marker, Aqu5. 
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Confocal microscopic examination identified GFP+/CD31+ BMDEPCs localized on the 
CD31+ endothelial layer of lung microvessels (Figure 3A). The GFP+ BMDEPCs were also 
Ve+, and localized on the Ve+ endothelial layer, but not localized on the Aqu5+ alveolar 
epithelial layer (Figure 3A). This result provides evidence for BMDEPC engraftment into 
the endothelial layer in the lung at active repair phase.
We quantified the engrafted BMDEPCs (CD45−/CD31+/eNOS+/GFP+) in lungs from mice 
8 weeks after saline or LPS injection, a time point when organ inflammation and 
inflammation-associated BMDEPC recruitment has been subsided. FACS analysis showed 
that number of CD45−/CD31+/eNOS+/GFP+ cells was approximately 121-fold higher in 
LPS-injected than in saline-injected lungs (Figures 3B and C), indicating an increased 
BMDEPC engraftment in injured lungs. These results provide cytological evidence for 
BMDEPC engraftment into lung microvessels and suggest that BMDEPC contribute to 
endothelial barrier repair.
Different contributions of RECs versus BMDEPCs to endothelial barrier repair
We next compare the relative contributions of RECs versus BMDEPCs to endothelial barrier 
repair. We counted the numbers of proliferating RECs and BMDEPCs in lungs at 48 hours, 
and the numbers of REC- and BMDEPC-derived new ECs in lungs 8 weeks after LPS-
induced injury. At 48 hours, number of proliferating RECs was 2.4-fold higher than 
proliferating BMDEPCs in LPS-challenged lungs, although both proliferating RECs and 
BMDEPCs were remarkably higher than control lungs (Figures 4A and 4B). In lungs 8 
weeks after LPS-induced injury, total number of new ECs, defined as CD45−/CD31+/BrdU
+ cells, accounted for approximately 2% of total lung cells, which is in agreement with our 
previous observation that apoptotic ECs accounted for about 2% of total lung cells in this 
mouse model of ALI.30 Among the new EC subpopulation, 83% were rtTA+ (REC-
derived), but only 9.5% were GFP+ (BMDEPC-derived) (Figures 4C and D).
BMDEPCs may replace apoptotic/dead ECs by differentiation.9 We compared number of 
REC-derived ECs (CD45−/CD31+/BrdU+/rtTA+ cells) to number of total engrafted 
BMDEPCs (CD45−/CD31+/eNOS+/GFP+ cells), which includes BrdU+ and BrdU-, 
BMDEPC-derived ECs, in lungs of EC-rtTA-GFP-BM mice (Supplemental Table II) 8 
weeks after LPS injection. REC-derived ECs constituted 22%, but the total engrafted 
BMDEPCs constituted only 3.7% of the total CD45−/CD31+ EC population (Figure 4E). 
Thus, both histological and FACS analyses revealed that RECs is a major source and 
BMDEPCs is a complementary source of new ECs in endothelial barrier repair in the lungs.
Targeted inhibition of REC or BMDEPC intrinsic NF-κB activity suppresses REC or 
BMDEPC proliferation
We previously demonstrated that Dox-induced I-κBαmt expression inhibited NF-κB in 
endothelial lineage cells, but not in other cell types in the EC-I-κBαmt mice.31 Using the 
EC-I-κBαmt mice as recipients or donors, we generated EC-I-κBα-WT-BM or WT-EC-I-
κBα-BM chimeras (Supplemental Table II). We confirmed high level of donor BM 
engraftment (>95%) in the chimeras (Supplemental Figures IB and IC). EC-I-κBα-WT-BM 
or WT-EC-I-κBα-BM mice overexpress I-κBαmt on RECs or BMDEPCs and enabled us to 
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selectively block REC or BMDEPC intrinsic NF-κB activity through Dox-induced I-κBαmt 
expression, which leads to the suppression of REC or BMDEPC proliferation.
At 48 hours post-LPS, tissue NF-κB activity is reduced to a low level. Techniques (IF, IHC) 
capable of revealing EC-selective NF-κB inhibition are not sensitive enough to detect the 
subtle change in NF-κB activity caused by Dox-induced I-κBmt expression. We verified 
that treatment of the chimeras with Dox induces I-κBαmt expression and inhibits NF-κB 
activity. We showed that injection of EC-I-κBα-WT-BM mice with Dox at 36 hours post-
LPS induced high level of I-κBαmt mRNA expression (Supplemental Figure III), and 
repressed lung tissue level of vascular cell adhesion molecule (VCAM)-1 protein, a widely 
used marker of endothelial NF-κB activity, at 48 hours (Figure 5A).
Targeted inhibition of REC or BMDEPC intrinsic NF-κB activity suppressed REC or 
BMDEPC proliferation. At 48 hours after LPS and 12 hours after Dox injection, number of 
proliferating RECs or BMDEPCs in lung sections of EC-I-κBα-WT-BM or WT-EC-I-κBα-
BM mice (Supplemental Table II, with NF-κB inhibition) were significantly lower than in 
lung sections of EC-rtTA-GFP-BM or WT-EC-rtTA-BM mice (Supplemental Table II, 
without NF-κB inhibition) (Figures 5B and 5C).
Suppression of REC or BMDEPC proliferation at active repair phase was associated with 
an augmented endothelial permeability
At 48 hours after LPS and 12 hours after Dox injection, WT mice, in which REC or 
BMDEPC proliferation was not inhibited, displayed a moderate increase in endothelial 
permeability that is consistent with endothelial barrier repair phase (Figure 5D). EC-I-κBα-
WT-BM or WT-EC-I-κBα-BM mice, in which REC or BMDEPC proliferation was 
inhibited, exhibited a significantly augmented endothelial permeability (Figure 5D). 
Blockade of REC intrinsic NF-κB activity caused a 42% reduction in REC proliferation and 
41% augmentation of endothelial permeability in the EC-I-κBα-WT-BM mice (Figures 5B 
vs 5D), suggesting that augmentation of endothelial permeability and suppression of REC 
proliferation are causally related.
Proliferation-independent mechanisms do not contribute to the augmented endothelial 
permeability caused by endothelial NF-κB blockade at 48 hours
In addition to controlling EC proliferation, NF-κB mediates endothelial permeability by 
inducing inflammatory gene expression26 and by disrupting inter-endothelial junctions, as 
results of myosin light chain (MLC) phosphorylation, and junction protein internalization 
and down-regulation.33-36 To clarify whether these proliferation-independent mechanisms 
my contribute to the augmented endothelial permeability caused by endothelial NF-κB 
blockade at 48 hours, we compared lung tissue levels of NF-κB-regulated cytokines, TNF-α, 
IL-1β, IL-6, and chemokine (C-X-C motif) ligand 1, between mice at 6 and 48 hours to 
assess organ inflammatory status at 48 hours, and between WT and EC-I-κBαmt mice to 
examine the effects of endothelial NF-κB blockade. We used EC-I-κBαmt mice 
(Supplemental Table I), the recipients or donors of EC-I-κBα-WT-BM or WT-EC-I-κBα-
BM chimeras (Supplemental Table II), for these studies. The use of EC-I-κBαmt mice 
enabled us to evaluate the effects of inhibiting REC and BMDEPC intrinsic NF-κB activities 
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simultaneously. We also compared tissue levels of phospho-MLC2 and membrane-bound 
VE-cadherin, two major markers of disruption of inter-endothelial junctions33-36, between 
the two time points and the two groups of mice.
Lung tissue levels of the 4 cytokines at 48 hours were higher than controls, but were many-
fold lower than at 6 hours, and, importantly, were not affected by EC-restricted NF-κB 
inhibition (Supplemental Figures IVA to IVD). At 48 hours post-LPS, lung tissue levels of 
phospho-MLC2, and membrane-bound and cytoplasmic VE-cadherin proteins were all at 
control levels, and were not affected by EC-restricted NF-κB inhibition (Supplemental 
Figures IVE, IVF and V). By contrast, lung tissue level of phospho-MLC2 was several-fold 
higher at 3 hours, and level of membrane-bound or cytoplasimic VE-cadherin protein was 
several-fold lower or higher at 6 hours than controls and at 48 hours, indicating increased 
MLC2 phosphorylation and VE-cadherin internalization at 6 hours, but not at 48 hours. All 
these changes were abrogated by EC-restricted NF-κB blockade (Supplemental Figures IVE, 
IVF and V). This result excludes the possible involvement of NF-κB-mediated, 
proliferation-independent mechanisms in the augmentation of endothelial permeability 
caused by endothelial NF-κB blockade at 48 hours.
Discussion
This study addresses three fundamental questions that are critical for the understanding of 
cellular mechanisms of endothelial barrier restoration following inflammatory organ injury. 
First, what are the origins of ECs in endothelial barrier repair and restoration? We 
demonstrated for the first time that both RECs and BMDEPCs are important sources of new 
ECs in endothelial barrier restoration. Recovery of endothelial barrier function was 
associated with a remarkably increased REC proliferation, and increased BMDEPC 
proliferation and engraftment. Lungs at active barrier repair phase had the highest level of 
REC or BMDEPC proliferation, and increased BMDEPC engraftment. In lungs 8 weeks 
after LPS-induced injury, numbers of REC- and BMDEPC-derived ECs increased by 22- 
and 121-fold, respectively. More importantly, suppression of REC or BMDEPC 
proliferation at active barrier repair phase (48 hours) was associated with an augmented 
endothelial permeability and impeded endothelial barrier recovery.
Second, what role does each EC precursor cell play in endothelial barrier restoration? We 
showed that although both RECs and BMDEPCs participate in endothelial barrier repair, 
their quantitative contributions differ. In lungs at active barrier repair phase, number of 
proliferating RECs was more than double of proliferating BMDEPCs. In lungs 8 weeks after 
LPS-induced injury, REC-derived ECs constituted 22%, but BMDEPC-derived ECs 
constituted only 3.7% of the total CD45−/CD31+ ECs. This result illustrates that REC is a 
major and BMDEPC is a complementary source of new ECs in endothelial barrier 
restoration following inflammatory ALI.
RECs and BMDEPCs also play different roles in maintaining normal endothelium. In lungs 
of mice 8 weeks after saline injection, we detected 1.07% REC-derived new ECs (CD45−/
CD31+/rtTA+/BrdU+), but only 0.03% BMDEPC-derived ECs (CD45−/CD31+/eNOS
+/GFP+) in the EC population (CD45−/CD31+), suggesting that maintenance of normal 
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endothelium depends mainly on proliferation of RECs with minimal contribution by 
BMDEPCs. This result is in agreement with a prior report showing that maintenance of lung 
endothelium does not involve BMDEPCs.15
Third, is there a causal link between REC or BMDEPC proliferation and endothelial barrier 
restoration? This is the most important question that no previous study has attempted to 
address, due to technical challenges. Cell proliferation is regulated by many signaling 
pathways and numerous cell cycle regulators with overlapping functions.37, 38 The 
redundancy in the regulatory mechanisms makes it extremely difficult to achieve a clear-cut 
and high-level inhibition of REC or BMDEPC proliferation by targeting any single 
proliferation pathway. Additionally, many of the proliferation-regulating pathways also 
regulate other biological processes. This compromises the selectivity in inhibiting cell 
proliferation. We may not be able to completely overcome the technical huddles using 
currently available animal models, but have to find a way to address this important question. 
In this study, we used REC- or BMDEPC-restricted inhibition of NF-κB activity as a means 
of suppressing REC or BMDEPC proliferation. We did so for 3 reasons: first, the NF-κB 
pathway is a major signaling pathway controlling cell proliferation.25-29 second, animal 
models are available in our laboratory31 and third, inhibition of NF-κB-mediated EC 
proliferation and inhibition of NF-κB-mediated, proliferation-independent mechanisms have 
opposite effects on endothelial permeability, which allow us to reliably assess the effect of 
inhibiting REC or BMDEPC proliferation on endothelial barrier restoration. We found that 
inhibition of REC or BMDEPC intrinsic NF-κB activity repressed REC or BMDEPC 
proliferation by 42% or 44%, implicating the important role of NF-κB pathway in 
controlling REC and BMDEPC proliferation, and illustrating the effectiveness of blocking 
NF-κB pathway in repressing REC or BMDEPC proliferation.
Suppression of REC or BMDEPC proliferation by REC- or BMDEPC-restricted NF-κB 
blockade at 48 hours was associated with an augmented endothelial permeability. We 
interpret this augmentation, at least partially, as a consequence of suppressing REC or 
BMDEPC proliferation. EC apoptosis is a major mechanism underlying the higher 
endothelial permeability at 48 hours post-LPS.30, 39 Replacement of the apoptotic/dead ECs 
through proliferation of endothelial precursor cells (RECs and BMDEPCs) is critical to the 
restoration of endothelial barrier function. When REC or BMDEPC proliferation is 
repressed, particularly at active barrier repair phase, the process of endothelial barrier repair 
is impeded and endothelial permeability increased. In supporting this contention, we 
demonstrated here that selective blockade of REC or BMDEPC intrinsic NF-κB activity at 
48 hours suppressed REC or BMDEPC proliferation and concomitantly augmented 
endothelial permeability. Others have demonstrated a causal link between EC apoptosis and 
increased endothelial permeability.40-42. Our previous study showed that inhibition of EC 
apoptosis ameliorated the augmentation of endothelial permeability caused by endothelial 
NF-κB blockade at 48 hours in this ALI model.30,39
In addition to controlling EC proliferation, NF-κB mediates LPS-induced endothelial 
permeability by inducing inflammatory gene expression,26 which causes the disruption of 
inter-endothelial junctions as results of MLC phosphorylation, EC contraction and junction 
protein cytosolic translocation.33-36 However, these mechanisms are unlikely to contribute 
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to the augmented endothelial permeability caused by REC- or BMDEPC-targeted NF-κB 
inhibition at 48 hours. At this stage, tissue levels of NF-κB-regulated cytokines have 
become very low and were not affected by endothelial NF-κB blockade. Tissue levels of 
phospho-MLC and membrane-bound VE-cadherin, two major markers of disruption of inter-
endothelial junctions, were at control levels, suggesting that the LPS-induced disruption of 
inter-endothelial junctions has been restored at this time point. More importantly, it is well 
documented that inhibitions of NF-κB-mediated inflammatory cytokine expression and NF-
κB-mediated disruption of inter-endothelial junctions decrease, but not increase endothelial 
permeability.31, 33-36
Other factors may also contribute to the augmentation. NF-κB blockade in BMDEPCs may 
inhibit BMDEPC migration, adhesion and incorporation, which can impede BMDEPC-
mediated barrier repair. However, this mechanism may not contribute to the augmented 
endothelial permeability caused by REC-selective NF-κB blockade. Neighboring RECs 
replace apoptotic/dead ECs by proliferating in situ on the endothelial layer, and by sprouting 
toward the injured site,6 a process that may not involve significant cell migration and 
incorporation. To restore endothelial barrier function, the newly generated ECs need to 
interact with the existing ECs on the endothelial layer to re-establish normal inter-
endothelial junctions. The effects of NF-κB blockade on these cell-cell interactions warrant 
further investigation. Collectively, these results suggest that suppression of REC or 
BMDEPC proliferation explains, at least partially, the augmented endothelial permeability 
caused by blockade of REC or BMDEPC intrinsic NF-κB activity at 48 hours, implying a 
causal relationship between REC or BMDEPC proliferation and endothelial barrier 
restoration.
We demonstrated previously that endothelial NF-κB blockade at 6 hours inhibited LPS-
induced endothelial permeability, 31 but showed here that REC- or EPC-targeted NF-κB 
inhibition at 48 hours augmented endothelial permeability. This discrepancy could be 
explained by different biological function that NF-κB plays at the two time points. At 6 
hours, NF-κB mediates the increased endothelial permeability by disrupting inter-
endothelial junctions33-36 without involving significant EC apoptosis.30, 39 Endothelial NF-
κB blockade at this stage abrogated the disruption of inter-endothelial junctions, but had 
little effect on EC apoptosis, resulting in a reduced endothelial permeability. At 48 hours, 
the disrupted inter-endothelial junctions have been fully restored and EC apoptosis has 
become a predominant mechanism underlying the increased endothelial permeability. 
Endothelial NF-κB blockade at this stage inhibited NF-κB-mediated EC proliferation and 
promoted EC apoptosis,30,39 both of which impeded barrier recovery and augmented 
endothelial permeability. Consistent with this explanation, we showed here that tissue level 
of phospho-MLC or membrane-bound VE-cadherin was remarkably high or low at 6 hours, 
but was at control level at 48 hours. Endothelial NF-κB blockade abrogated LPS-induced 
increase in tissue level of phospho-MLC, decrease in tissue level of membrane-bound VE-
cadherin and increase in VE-cadherin internalization at 6 hours, but had no effect at 48 
hours. Our previous study showed that endothelial NF-κB blockade at 48 hours enhanced 
EC apoptosis and concomitantly augmented endothelial permeability.39 Others have 
demonstrated a causal link between EC apoptosis and increased endothelial 
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permeability.40-42 Although the number of apoptotic/dead ECs is only a small fraction of 
total ECs, EC apoptosis/death leads to the formation of pores on endothelium, which 
dramatically increase endothelial leakiness.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ALI acute lung injury
Aqu5 aquaporin-5
BMDEPCs bone marrow-derived endothelial progenitor cells
BMMNCs bone marrow mononuclear cells
BrdU bromodeoxyuridine
DAPI 4',6-diamidino-2-phenylindole
Dox doxycycline
EC endothelial cell
eNOS endothelial nitric oxide synthase
EBD Evans blue dye
EPCs endothelial progenitor cells
FACS fluorescence activated cell sorting
GFP green fluorescent protein
IF immunofluorescence
Pro-3 TO-PRO-3 dye
VE-cad VE-cadherin
MLC2 myosin light chain 2
RECs resident endothelial cells
rtTA reverse tetracycline transactivator
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Significance
Disruption of endothelial barrier integrity and increase in endothelial leakiness are 
hallmarks of acute lung injury and other inflammatory conditions. However, the origin 
and function of new endothelial cells in endothelial barrier repair and restoration are 
unknown. Using novel transgenic mouse models, this study identifies resident endothelial 
cell (REC) as a major source and bone marrow derived endothelial progenitor cell 
(BMDEPC) as a complementary source of new ECs in endothelial barrier repair and 
restoration. We provide the first evidence that RECs and BMDEPCs play important 
functions in endothelial barrier restoration, and demonstrate a causal relationship 
between REC or BMDEPC proliferation and endothelial barrier restoration. Our data 
provides important new insights into cellular mechanisms of endothelial barrier repair 
and restoration.
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Figure 1. Endothelial barrier recovery is associated with increased resident endothelial cell 
(REC) and bone marrow derived endothelial progenitor (BMDEPC) proliferation
A: Endothelial permeability in lungs was measured using Evan blue dye (EBD) leakage 
index at indicated time (hours) after saline (Con) or LPS (5 mg/kg, i.p.) injection. Means ± 
SEM of 6 mice per group. *, p< 0.0.5, compared to control.
B to D: Lung cryosections were prepared at indicated time (hours) after LPS and 4 hours 
after 5-bromo-2-deoxyuridine (BrdU) injection, stained with BrdU plus rtTA (reverse 
tetracycline transactivator), BrdU plus GFP (green fluorescence protein) or GFP antibodies, 
and nuclei counterstained with DAPI (4, 6-diamidino-2-phenylindole). Number of BrdU+/
rtTA+ proliferating RECs (B), BrdU+/GFP+ proliferating BMDEPCs (C) or GFP+ recruited 
BMDEPCs (D) was counted and expressed as a percentage of total cells as revealed by 
DAPI nuclear staining. Mean ± SEM of 5 mice per group. *, p < 0.05, compared to controls.
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Figure 2. RECs participate in endothelial repair
A: RECs proliferate in situ on the endothelial layer at active repair phase. Lung sections 
from mice 48 hours after LPS injection were stained with antibodies against proliferative 
marker, BrdU, REC marker, rtTA, EC marker, CD31, and alveolar epithelial cell marker, 
aquaporin-5 (Aqu5), and nuclei counterstained with TO-PRO-3 dye (Pro-3). 3D projections 
(A1-A6) or single images (A7-A10) of confocal z-stacks are shown. A1, BrdU+ staining 
(green) detects proliferating cells (light blue nuclei). Blue, Pro-3 nuclear staining. A2, rtTA+ 
staining (red) detects RECs and visualizes the endothelial layer. A3, Merge of A1 and A2 
shows BrdU+/rtTA+ RECs (arrow indicated) localized on rtTA+ endothelial layer of 
alveolar microvessels. A4 and A5, Orthogonal view (X-Y, X-Z and Y-Z) of the boxed area 
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in A3 at higher magnification confirms colocalization of BrdU+ and rtTA+ signals, and 
colocalization of BrdU+ and Pro-3+ stainings. Note, the blue nuclear staining in A4 or the 
red rtTA staining in A5 was omitted for clarity. A6 and A7, BrdU+/CD31+ RECs (arrow 
indicated) are localized on CD31+ endothelial layer of alveolar microvessels. A8-A10, 
Higher magnification of the boxed area in A7 is shown. A8, BrdU (green) and CD31 (red) 
double stain shows that BrdU+ proliferating REC is localized on CD31+ endothelial layer 
(red). A9, BrdU (green) and Aqu5 (blue) double stain shows that BrdU+ proliferating REC 
is not localized on Aqu5+ epithelial layer (blue). A10, Merge of A8 and A9 confirms that 
BrdU+ REC is localized on the endothelial layer (red) between two epithelial layers (blue). 
Scale bars: A1, A2, A3, A6 and A7, 40 μm; A4 and A5, 8 μm; A8, A9 and A10, 3 μm.
B and C: Fluorescence activated cell sorting (FACS) pictures (B) and bar graph (C) show an 
increased number of REC-derived ECs, defined as CD45−/CD31+/rtTA+/BrdU+ cells, in 
lungs of mice 8 weeks after LPS injection, compared to saline-injected mice (Con). Mean ± 
SEM of 5 mice per group. *, p < 0.05, compared with control.
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Figure 3. BMDEPCs contribute to endothelial repair
A: BMDEPCs engraft into microvessel wall. Lung sections from mice 48 hours after LPS 
injection were stained with antibodies against BMDEPC marker, GFP, EC markers, CD31 
and Ve-cadherin (Ve), alveolar epithelial cell marker, Aqu5, and nuclei counterstained with 
Pro-3 dye. 3D projections (A1 to A6) or single images (A7 to A10) of confocal z-stacks are 
shown. A1, GFP+ (green) staining identifies BMDEPCs. A2, CD31+ (red) staining 
visualizes the endothelial layer. A3, Merge of A1 and A2 shows engrafted (GFP+/CD31+) 
BMDEPCs (yellow cells) localized on CD31+ endothelial layer (red). A4 and A5, 3D (A4) 
or orthogonal (A5) projection of the boxed area in A3 at higher magnification confirms 
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GFP/CD31 co-expression on the same individual BMDEPC. For clarity, the blue nuclear 
staining was omitted. A6 and A7, GFP+/Ve+ BMDEPCs (arrow indicated) are localized on 
Ve+ endothelial (red), but not on Aqu5+ epithelial (blue) layer. High magnification of the 
boxed area in A7 is shown in A8-A10. A8, GFP (green) and Ve (red) double staining shows 
that GFP+ BMDEPCs express Ve (yellow cells), and are localized on Ve+ endothelial layer. 
A9, GFP (green) and Aqu5 (red) Double staining shows that GFP+ BMDEPCs do not 
express Aqu5 (green cells), and are not localized on Aqu5+ epithelial layer. A10, GFP 
(green), Ve (red) and Aqu5 (blue) triple staining confirms that GFP+ BMDEPCs (yellow 
cells) are localized on endothelial (red), but not on epithelial (blue) layer. Scale bars: A1, 
A2, A3, A6 and A7, 40μm; A4, A5, A8, A9 and A10, 8 μm.
B and C: FACS pictures (B) and bar graph (C) show increased numbers of GFP+/CD31+ 
cells in the CD45−/CD31+/eNOS+ EC population in lungs of mice 8 weeks after LPS 
injection, compared to lungs of mice 8 weeks after saline injection (Con), indicating an 
increased BMDEPC engraftment. Mean ± SEM of 5 mice per group. *, p < 0.05, compared 
to control mice.
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Figure 4. RECs and BMDEPCs contribute differently to endothelial barrier repair
A: Representative micrographs of rtTA plus BrdU (RECs) or GFP plus BrdU (BMDEPCs) 
double staining of lung sections from EC-rtTA-GFP-BM mice 48 hours after saline (Con) or 
LPS injection. Number of rtTA+/BrdU+ proliferating RECs was significantly higher than 
number of GFP+/BrdU+ proliferating BMDEPCs (arrows indicated). Scale bars, 75 μm.
B: Bar graph shows higher number of proliferating RECs (red bars) than proliferating 
BMDEPCs (black bars) in lungs at 48 hours post-LPS. Mean ± SEM of 5 mice per group. *, 
p < 0.05, compared to BMDEPCs at 48 hours.
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C and D: FACS pictures (C) and bar graph (D) show that lung cells from EC-rtTA-GFP-BM 
mice 8 weeks after LPS injection have a remarkably higher number of REC-derived (rtTA+/
CD31+) than BMDEPC-derived (GFP+/CD31+) ECs in the CD45−/CD31+/BrdU+ new EC 
population. Mean ± SEM of 5 mice per group. *, p < 0.05, compared to BMDEPCs.
E: Bar graph shows higher number of REC-derived new ECs (CD45−/CD31+/BrdU+/rtTA
+) than engrafted BMDEPCs (CD45−/CD31+/eNOS+/GFP+) in lung cells from EC-rtTA-
GFP-BM mice 8 weeks after LPS injection. Mean ± SEM of 5 mice per group. *, p < 0.05, 
compared to engrafted BMDEPCs.
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Figure 5. Targeted suppression of REC or BMDEPC proliferation at barrier repair phase 
augments endothelial permeability
Wild type (WT), EC-rtTA-GFP-BM (rtTA-GFP), EC-I-κB-WT-BM (I-κB-WT), WT-EC-
rtTA-BM (WT-rtTA) and WT-EC-I-κBα-BM (WT-I-κB) mice (see Supplemental Table II) 
were injected with saline (Con) or LPS (48 Hrs), and then with Dox (0.5 mg/mouse, i.p.) 36 
hours after LPS injection. At 48 hours after LPS, lung cryosections were prepared or tissue 
level of vascular cell adhesion molecule (VCAM)-1 protein determined, or lung endothelial 
permeability measured using EBD index.
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A: Western blot photographs show that Dox-induced I-κBαmt expression at 48 hours 
reduces lung tissue level of VCAM-1 protein, an NF-κB-dependent gene product, in EC-I-
κB-WT-BM mice, indicating an inhibition of REC NF-κB activity. TA-C, EC-rtTA-GFP-
BM control, I-κB-C, EC-I-κB-WT-BM control, TA48, EC-rtTA-GFP-BM 48 hours, and I-
κB48, EC-I-κB-WT-BM 48 hours. Representative of 3 independent experiments.
B: and C: Bar graphs show that targeted blockade of REC or BMDEPC intrinsic NF-κB 
activity suppresses REC or BMDEPC proliferation. Lung cryosections were stained with 
BrdU plus rtTA antibodies and nuclei counterstained with DAPI. Number of BrdU+/rtTA+ 
proliferating RECs (B) or BrdU+/rtTA+ proliferating BMDEPCs (C) was counted and 
expressed as a percentage of total BrdU+ cells. Mean ± SEM of 5 mice per group. *, p < 
0.05, compared to Con groups. #, p < 0.05, compared with 48 hour group of rtTA-GFP or 
Wt-rtTA mice.
D: Suppression of REC or BMDEPC proliferation by REC- or BMDEPC-targeted NF-κB 
blockade was associated with an impeded endothelial barrier recovery. Inhibition of REC 
(white vs black bars) or BMDEPC (white vs grey bars) proliferation was associated with an 
augmented endothelial permeability. Mean ± SEM of 8 mice per group. *, p < 0.05, 
compared with Con groups. #, p < 0.05, compared with WT-48 hour group.
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